The Fox Chase Cancer Center is under new leadership since the last review and continues as one of the nation's few free standing comprehensive cancer centers. The Center's mission is """"""""To prevail over cancer, marshaling excellence of heart and mind each day in the collaborative practice of bold scientific discovery, prevention strategies, and compassionate cancer care."""""""" Our vision is to be an acknowledged national leader in cancer research and medicine and a pre-eminent cancer center in the Philadelphia area. The new leadership in conjunction with advice from External Advisory Boards has consolidated the CCSG Research Programs from 11 to 5. These five Programs represent the core scientific strengths of the Fox Chase Cancer Center. At the last review 30 CCSG Shared Facilities and 2 support elements (Protocol Review and Monitoring System and Protocol Specific Research) were approved for funding with recommendations to consolidate facilities. This proposal requests partial support for 16 core facilities and 2 support elements. Developmental Funds are requested to strategically increase critical mass for these 5 research Programs over the CCSG funding cycle. A plan is presented to recruit 21 to 30 new and replacement investigators. In the past CCSG cycle, 40 investigators were recruited and, with the exclusion of our 17 newest recruits, 19 of 23 (83%) have obtained $15.4 million in peer-reviewed funding within 24 months of their appointment. Of that amount $5.1 million was garnered by investigators who were partially supported by Developmental Funds. Since the last submission, the Cancer Research Pavilion was completed as planned in 2010 and will provide much of the needed space for new investigator laboratories. The Leadership's vision includes a plan to increase team-based science via strategic keystone investments. These institutional investments are intended to expand the research portfolio of FCCC to include more """"""""team-based"""""""" grants such as Program Project Grants and SPOREs. Several team-based science grant proposals will be submitted over the next few years as a direct result of these keystone Investments. To meet the demand presented by a future increase in principal investigators, the Center plans to leverage $8 million of ARRA funds with $5.1 million of institutional investment to construct a Comparative Medical Facility (CMR). Since the last review, FCCC has implemented a formal review mechanism to evaluate and prioritize its CCSG Shared Research Resources. As a result, of this evaluation process, the number of Shared Research Resources has been streamlined.

Public Health Relevance

NCI-designated Cancer Centers such as Fox Chase Cancer Center serve as major source of discovery of the nature of cancer, and development of more effective approaches to prevention, diagnosis and therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA006927-50S3
Application #
8712614
Study Section
Subcommittee G - Education (NCI)
Program Officer
Shafik, Hasnaa
Project Start
1997-07-21
Project End
2014-06-30
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
50
Fiscal Year
2013
Total Cost
$300,000
Indirect Cost
$131,933
Name
Research Institute of Fox Chase Cancer Center
Department
Type
DUNS #
064367329
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Ross, Kayleigh C; Chin, Kevin F; Kim, Daehwan et al. (2018) Methotrexate sensitizes drug-resistant metastatic melanoma cells to BRAF V600E inhibitors dabrafenib and encorafenib. Oncotarget 9:13324-13336
Diefenbach, Michael A; Benedict, Catherine; Miller, Suzanne M et al. (2018) Examining the impact of a multimedia intervention on treatment decision-making among newly diagnosed prostate cancer patients: results from a nationwide RCT. Transl Behav Med 8:876-886
Shafi, Ayesha A; Schiewer, Matthew J; de Leeuw, Renée et al. (2018) Patient-derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response. Eur Urol Oncol 1:325-337
Mazor, Anna M; Mateo, Alina M; Demora, Lyudmila et al. (2018) Breast conservation versus mastectomy in patients with T3 breast cancers (>?5 cm): an analysis of 37,268 patients from the National Cancer Database. Breast Cancer Res Treat :
Ingram, Justin P; Tursi, Sarah; Zhang, Ting et al. (2018) A Nonpyroptotic IFN-?-Triggered Cell Death Mechanism in Nonphagocytic Cells Promotes Salmonella Clearance In Vivo. J Immunol 200:3626-3634
Chang, Wen-Chi L; Jackson, Christina; Riel, Stacy et al. (2018) Differential preventive activity of sulindac and atorvastatin in Apc+/Min-FCCCmice with or without colorectal adenomas. Gut 67:1290-1298
Mishra, Om P; Popov, Anatoliy V; Pietrofesa, Ralph A et al. (2018) Synthetic secoisolariciresinol diglucoside (LGM2605) inhibits myeloperoxidase activity in inflammatory cells. Biochim Biophys Acta Gen Subj 1862:1364-1375
Mortazavi, S M J; Bevelacqua, J J; Fornalski, K W et al. (2018) Comments on ""Space: The Final Frontier-Research Relevant to Mars"". Health Phys 114:344-345
Esposito, Andrew C; Crawford, James; Sigurdson, Elin R et al. (2018) Omission of radiotherapy after breast conservation surgery in the postneoadjuvant setting. J Surg Res 221:49-57
Dong, Yanqun; Zaorsky, Nicholas G; Li, Tianyu et al. (2018) Effects of interruptions of external beam radiation therapy on outcomes in patients with prostate cancer. J Med Imaging Radiat Oncol 62:116-121

Showing the most recent 10 out of 1280 publications